Skip to main content
Clinical Trials/ISRCTN06653773
ISRCTN06653773
Completed
未知

A double blind placebo-controlled randomised trial of the addition of mirtazapine for patients with depression in primary care who have not responded to at least 6 weeks of treatment with a selective serotonin reuptake inhibitor or serotonin and noradrenaline reuptake inhibitor.

niversity of Bristol (UK)0 sites400 target enrollmentSeptember 20, 2012

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Bristol (UK)
Enrollment
400
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Registry
who.int
Start Date
September 20, 2012
End Date
June 30, 2016
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Bristol (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 18\-75 years
  • 2\. Currently taking any of the following SSRI or SNRI antidepressants, for at least 6 weeks at recommended (BNF) doses:
  • 2\.1\. Fluoxetine
  • 2\.2\. Sertraline
  • 2\.3\. Citalopram
  • 2\.4\. Escitalopram
  • 2\.5\. Fluvoxamine
  • 2\.6\. Paroxetine
  • 2\.7\. Duloxetine
  • 2\.8\. Venlafaxine and who have done so for at least 6 weeks at

Exclusion Criteria

  • GPs will be asked to exclude patients who have bipolar disorder, psychosis or alcohol/substance abuse/dependence or who are pregnant. In addition, we will exclude patients who: are not able to complete the study questionnaires or have a past history of an adverse reaction to mirtazapine.

Outcomes

Primary Outcomes

Not specified

Similar Trials